Kermer, Pawel http://orcid.org/0000-0001-5933-0985
Schellinger, Peter D.
Ringleb, Peter A.
Köhrmann, Martin
Article History
Received: 14 January 2022
Accepted: 11 February 2022
First Online: 17 February 2022
Declarations
:
: Not applicable.
: Not applicable.
: During the last 3 years PK received speaker´s honoraria from Biogen, Boehringer Ingelheim, Daiichi Sankyo, Pfizer/BMS and Roche. MK has received speaker’s honoraria and/or compensation for advisory board participation from: BI, Bayer, Daiichi Sankyo, Pfizer, BMS, Allm, AstraZeneca, Sanofi, Abbvie, Biogen, Amgen, Medtronic, Stryker, Compugroup Medical, Acticor. PS has received in the last 2 years honoraria and travel grants for participation in clinical trials, contribution to advisory boards or oral presentation from: Boehringer Ingelheim, Pfizer, and Daiichi-Sankyo. PR received lecture-fees and travel-expenses from Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer and compensation for advisory board participation from Boehringer Ingelheim, Covidien, and Daiichi Sankyo.